Stability-Indicating RP-HPLC Method for Determination of Guanfacine Hydrochloride in Bulk Drugs and in Pharmaceutical Dosage Form by Vinod K. Ahirrao et al.
 
Int. J. Ind. Chem., Vol. 2, No. 2, 2011, pp. 69-77 
 
International Journal of Industrial Chemistry 
 
www.ijichem.org   
Islamic Azad University 
Quchan Branch 
ISSN (online): 2228-5547 
ISSN (print): 2228-5970 
 
69 
 
Stability-Indicating RP-HPLC Method for Determination of Guanfacine 
Hydrochloride in Bulk Drugs and in Pharmaceutical Dosage Form 
 
Vinod K. Ahirrao
a, Dnyaneshwar R. Sangale
a, Vinayak S. Sonekar
a, Vinod V. Thorat
a, Rajendra P. Marathe
b, 
Rajesh B. Nawale
b, and Rajendra P. Pawar
a* 
 
aDepartment of Chemistry, Deogiri College, Aurangabad- 431004 (MS), India 
bGovernment college of Pharmacy Aurangabad-431004 (MS), India 
*Email: rppawar@yahoo.com 
 
Received: 2 December 2010; Accepted: 31 December 2010 
 
Abstract 
A  novel  stability-indicating  RP-HPLC  method  was  developed  and  validated  for  quantitative  determination  of 
guanfacine hydrochloride in bulk drug and in pharmaceutical dosage form. An isocratic, reversed phase HPLC method was 
developed to separate the drug from the degradation products, using Apollo, C18 (250mm x 4.6mm, 5µm) column with 
mobile phase of 50mM Ammonium acetate (volatile buffer) and acetonitrile (65:35, v/v). UV detection has been done at 
wavelength  220  nm.  The  guanfacine  hydrochloride  was  subjected  to  the  stress  conditions  of  hydrolysis  (acid,  base), 
oxidation, photolysis and thermal degradation. The stressed samples were analyzed by the proposed method. The analyte 
peak shape was excellent. The described method shows excellent linearity over a range of 30 – 450 µg/mL. The correlation 
coefficient for guanfacine hydrochloride was 0.999. The limit of detection for Guanfacine hydrochloride is 0.011 µg/mL 
and the limit of quantification is 0.038 µg/mL respectively. 
Degradation was observed for guanfacine hydrochloride in base, thermal and in 30% H2O2 conditions. The drug was 
found to be stable in the other stress conditions attempted. The degradation products were well resolved from main peak. 
The percentage recovery of guanfacine hydrochloride was ranged from (99.2% to 100.5%) in pharmaceutical dosage form. 
The  developed  method  was  validated  with  respect  to  the  linearity,  accuracy  (recovery),  precision,  specificity  and 
robustness. The forced degradation studies prove the stability indicating power of the method. 
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1. Introduction  
 
Guanfacine  hydrochloride  (Fig.  1)  is 
chemically  N-(diaminomethylidene)-2-(2,6-
dichlorophenyl)  acetamide  [1].  It  has  the 
cardiovascular  effect  of  lowering  blood 
pressure  [2].  It  is  an  agonist  of  the  α2A 
subtype of nor epinephrine receptors. These 
receptors  are  concentrated  heavily  in  the 
prefrontal  cortex  and  the  locus  coeruleus, 
with the potential to improve attention abilities 
via modulating post-synaptic α-2a receptors in 
the prefrontal cortex [3,4]. Drug lowered both 
systolic  and  diastolic  blood  pressure  by 
activating the central nervous system α-2a nor 
epinephrine  auto  receptors,  which  results  in 
reduced  peripheral  sympathetic  outflow  and 
thus causes a reduction in peripheral symphatic V. K. Ahirrao et al / Int. J. Ind. Chem., Vol. 2, No. 2, 2011, pp. 69-77 
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tone[5].  It  is  also  effective  in  treating  the 
symptoms of attention-deficit hyperactivity 
disorder  (ADHD)  and  also  used  in 
conjunction  with  stimulants  to  reduce, 
rebound, as well as induce, sleep [6]. 
Cl
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Fig.  1.  Chemical  structure  of  Guanfacine 
hydrochloride. 
 
Stability  testing  forms  is  an  important 
part  of  the  process  of  drug  product 
development.  The  purpose  of  stability 
testing  is  to  provide  evidence  on  how 
quality of a drug substance or drug product 
varies  with  time  under  the  influence  of  a 
variety  of  environmental  factors  such  as 
temperature,  humidity,  light  and  enables 
recommendation  of  storage  conditions, 
retest  periods  and  shelf  life  to  be 
established.  The  two  main  aspects  of 
stability  study  of  drug  product  plays  an 
important  role  in  shelf  life  determinations 
are  assay  of  active  drug  and  degradation 
products  generated  during  stability  study. 
The assay of drug product in  stability  test 
sample  needs  to  be  determined  using 
stability-indicating  method,  as 
recommended  by  the  international 
Conference  on  Harmonization  (ICH)  [7]. 
The objective of this work was to develop a 
simple,  precise  and  rapid  analytical  LC 
procedure,  which  would  be  serve  as 
stability-indicating assay method for dosage 
form of Guanfacine hydrochloride. 
A literature survey reveals that only one 
spectroflurometric  assay  method  was 
reported  for  guanfacine  hydrochloride 
presents  in  other  drugs[8].  A  GC-MS 
method  was  reported  to  determine 
guanfacine  in  Urine  [9].  One  scintillation-
proximity assay method were also reported for 
guanfacine  hydrochloride  [10].  A 
spectrophotometric analysis of guanafacine by 
acid-dye  and  charge  transfer  complexation 
method were also reported [11]. 
None of the reported analytical procedures 
describe  a  method  for  the  determination  of 
guanfacine  hydrochloride  in  pharmaceutical 
dosage  form  in  presence  of their  degradation 
products. 
In the present study attempts were made to 
develop  a  rapid,  economical,  precise  and 
accurate  method  for  the  estimation  of  the 
guanfacine hydrochloride in presence of their 
degradation products. This paper mainly deals 
with  the  forced  degradation  of  guanfacine 
hydrochloride under stress conditions like acid 
hydrolysis,  base  hydrolysis,  oxidation,  heat, 
light and validation of  the developed  method 
for  the  accurate  quantification  of  guanfacine 
hydrochloride  in  bulk  drug  and  solid  dosage 
form. 
 
2. Experimental 
2. 1. Chemicals 
99.7  %  purity  standard  of  Guanfacine 
hydrochloride  was  supplied  by  Mylan 
pharmaceutical  (Hyderabad,  India)  and  tablet 
Tenex  (2  mg)  were  purchased  from  market. 
Acetonitrile  (HPLC  grade)  were  purchased 
from Merck Fine Chemicals (Mumbai, India). 
Ammonium  acetate,  Sodium  hydroxide 
(NaOH),  hydrochloric  acid  (HCl)  and 
hydrogen  peroxide  (H2O2)  were  purchased 
from  Qualigens  fine  chemicals  (Glaxo  Ltd, 
Mumbai,  India). The 0.45  -Pump nylon filter 
was  obtained  from  Advanced  Micro  devices 
Pvt.  Ltd.,  (Ambala  Cantt,  India).  Double  -
distilled  water  was  used  throughout  the 
experiment.  Other  chemicals  used  were  of 
analytical or HPLC grade. 
 
2. 2. HPLC Instrumentation conditions 
HPLC  system  used  was  an  Agilent 
Technology  (1100  series,  Germany),  system 
equipped with auto sampler, quaternary pump, V. K. Ahirrao et al / Int. J. Ind. Chem., Vol. 2, No. 2, 2011, pp. 69-77 
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degasser  and  a  UV  Detector.  The  out-put 
signal  was  monitored  and  processed  using 
Agilent Chemstation software. The column 
used  was  C18,  5µm  (4.6  x  250  mm,  i.d., 
Apollo  technology,  Japan),  Column 
temperature was maintained to 30 C using 
column oven; the flow rate of mobile phase 
was  kept  1.0  mL/min.  The  mobile  phase 
consisted  of  50  mM  ammonium  acetate 
buffer-acetonitrile  (65:35  v/v).  The  buffer 
used  in  mobile  phase  contains  50  mM 
ammonium acetate filtered through 0.45µm 
nylon filter and degassed in ultrasonic bath 
prior  to  use.  Injection  volume  5  µL  and 
ultraviolet  (UV) detection  at 220 nm. The 
photodiode  array  detector  was  used  for 
analysis  of  forced  degradation  samples  in 
scan mode with a range of 200 – 400 nm. 
The  peak  homogeneity  was  expressed  in 
terms  of  peak  purity  and  was  obtained 
directly  from  the  spectral  analysis  report 
using above mentioned software.  
 
2. 3. Standard Solutions 
The standard stock solution (3.0mg/mL) 
of  guanfacine  hydrochloride  was  prepared 
by dissolving 75mg of working standard in 
diluent  (Water  :  Acetonitrile  70:30)  and 
diluting with the same solvent upto 25 mL. 
Standard solution was prepared from this 
stock  solution  by  transferring  10  mL 
standard  stock  solution  to  100  mL 
volumetric flask and diluted upto mark with 
diluent.  These  solutions  contained  300 
µg/mL
 Guanfacine hydrochloride.
 
 
2. 4. Sample Preparation of Dosage form
 
Twenty  tablets  of  mean  weight  were 
crushed in mortar. An amount of powdered 
mass  equivalent  to  30  mg  of  guanfacine 
hydrochloride  is  transferred  to  a  100  mL 
volumetric  flask.  The  drug  from  powder 
was  dissolved  and  extracted  with  the 
diluent.  To  ensure  complete  extraction  of 
drug  it  was  sonicated  for  25  min.  and 
diluted to 100mL. This solution was filtered 
through the 0.45 mm pump nylon filter. 
2. 5. Procedure for forced degradation  
2. 5. 1. Acidic Degradation 
15  mg  of  guanfacine  hydrochloride  was 
accurately  weighed  and  dissolved  in  5  mL 
diluent. 5 mL of 1.0 N HCl added and kept at 
room temparature about 3 h, then solution was 
neutralized  by  1.0  N  NaOH  to  pH  7  and 
volume made up to 50 mL with diluent. 
 
2. 5. 2. Alkali Degradation 
15  mg  of  guanfacine  hydrochloride  was 
accurately  weighed  and  dissolved  in  5  mL 
diluent. 5 mL of 0.1 N. NaOH were added and 
kept  at  60
  C  under  reflux  about  1  h  ,  then 
solution  was  neutralized  by  0.1N 
hydrochloride to pH 7 and volume made up to 
50 mL with diluent. 
 
2. 5. 3. Oxidative Degradation 
15  mg  of  guanfacine  hydrochloride  was 
accurately  weighed  and  dissolved  in  5  mL 
diluent. 5 mL of 30% H2O2 solution added and 
kept  at  60
  C  under  reflux  about  1h,  the 
solution  was  allowed  to  attended  ambient 
temperature. The volume make up to 50 mL 
with diluent. 
 
2. 5. 4. Thermal Degradation 
75 mg of drug substance was kept at 80 C 
for 24 h. The solution was prepared to achieve 
final concentration 300 µg/mL.
 
 
2. 5. 5. UV Degradation at 254 nm 
75  mg  of  drug  substance  was  exposed  to 
UV short (254 nm) light for 48 h. The solution 
was  prepared  to  achieve  final  concentration 
300 µg/mL.
 
 
2. 5. 6. UV Degradation at 366 nm 
75  mg  of  drug  substance  was  exposed  to 
UV long (366 nm) light for 48 h. The solution 
was  prepared  to  achieve  final  concentration 
300 µg/mL.
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3.  1.  Optimization  of  chromatographic 
conditions 
The primary target is the development of 
stability-indicating  HPLC  method  to 
achieve  the  resolution  between  guanfacine 
hydrochloride and its degradation products. 
To  achieve  the  separation  of  degradation 
products,  stationary  phases  of  C-18  and 
combination  of  mobile  phase  50mM 
ammonium  acetate  (volatile  buffer)  with 
acetonitrile  was  used.  The  separation  of 
degradation  product  and  guanfacine 
hydrochloride was achieved on Apollo ODS 
(Octadecyl  silane)  C18  stationary  phase 
column  and  50mM  ammonium  acetate  : 
acetonitrile (65:35 v/v) as a mobile phase at 
the column temperature 30 C. The tailing 
factor obtained was less than 2 and retention 
time was also about 7.0 min for main peak 
which would reduce the total run time and 
ultimately increase productivity and reduce 
the cost of analysis as per sample. Forced 
degradation study showed that the method is 
highly  specific  and  the  entire  degradation 
products were well resolved from the main 
peak. The developed method was found to 
be specific and valid as per ICH guidelines. 
System Suitability Parameters of Proposed 
RP-HPLC Method shown in Table 1. 
 
Table 1. System Suitability Parameters of Proposed 
RP-HPLC Method. 
 
Parameters  Guanfacine 
Hydrochloride 
Retention time (min)  7.2 
Tailing Factor  1.36 
Theoretical plates  11291 
 
3. 2. Result of forced degradation study 
Singh and Bakshi [12] suggested a target 
degradation of 20-80% for establishing the 
stability-indicating  nature  of  the  assay 
method,  as  even  intermediate  degradation 
products should not interfere with any stage 
of  drug  analysis.  Though  conditions  used 
for  forced  degradation  were  attenuated  to 
achieve degradation in the range of 20-80%, 
this could not be achieved in other degradation 
conditions  even  after  the  exposure  for 
prolonged  duration  except  base,  thermal  and 
oxidative degradation condition.  
In  basic conditions,  analyte undergoes  the 
degradation for the formation of both polar and 
non polar impurities. The percentage (%) base 
degradation  was  found  to  be  42.1%  with 
analyte peak having the peak purity 999.325.  
In oxidative degradation analyte undergoes 
degradation for the formation of both polar and 
non polar impurities within short time period. 
The percentage (%) degradation was found to 
be 59.2% with analyte peak  having the peak 
purity 999.293.  
In  thermal  degradation  analyte  undergoes 
degradation  for  the  formation  of  polar 
impurities.The thermal degradation percentage 
(%) was  found to be 8.9% with analyte peak 
having the peak purity 999.655. 
The Peak purity test results confirm analyte 
peak  is  homogeneous  in  all  the  stress 
conditions  tested.  The  mass  balance  of 
guanfacine hydrochloride in stress samples was 
close  to  100%  and  moreover,  the  unaffected 
assay  of  guanfacine  hydrochloride  in  the 
tablets confirms the stability- indicating power 
of  the  method.  The  summary  of  forced 
degradation studies is given in Table 2. 
Chromatographic  peak  purity  data  was 
obtained from the spectral analysis report and a 
peak purity value greater than 990 indicates a 
homogeneous peak. The peak purity values for 
analyte  peaks  was  in  the  range  of  999-1000 
indicating  homogeneous  peaks  and  thus 
establishing  the  specificity  of  assay  method. 
Fig. 2 shows the chromatogram of guanfacine 
hydrochloride  tablet  solution.  Fig.  4  shows 
chromatogram  of  guanfacine  hydrochloride 
standard solution. Fig. 6 shows chromatograms 
of  base hydrolysis degradation.  Fig. 8  shows 
the chromatogram of oxidative degradation and 
Fig.  9  shows  chromatograms  of  thermal 
degradation.  No  other  co-eluting  peaks  were 
found  with  the  mean  peaks  suggested  the 
specificity of the method for the estimation of V. K. Ahirrao et al / Int. J. Ind. Chem., Vol. 2, No. 2, 2011, pp. 69-77 
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guanfacine  hydrochloride  in  presence  of 
degradation products. 
 
4. Method Validation 
The described method was validated with 
respect  to  specificity,  linearity,  system 
suitability,  accuracy,  robustness,  LOD, 
LOQ  and  intermediate  precision. 
Characteristics  parameters  of  system 
suitability are given in Table 1.  
 
4. 1. Specificity 
Photodiode  array detection  was used as 
an evidence for the specificity of the method 
and to evaluate the homogeneity of the drug 
peak.  The  peak  purity  values  are 
determined. The peak purity were more than 
999 for drug substance and drug product at 
220  nm,  which  shows  that  the  peaks  of 
analyte  were  pure  and  also  formulation 
excipients, diluent peaks and degradation peaks 
were not interfering with analyte peak.  
 
Table 2. Results of analysis of forced degradation study 
samples  using proposed method, indicating percentage 
degradation  and  peak  purity  of  Guanfacine 
Hydrochloride. 
 
Stress 
conditions/duration 
(%) 
Degradation 
Peak purity 
data* 
Acidic/1.0N 
hydrochloride/ RT/3h  0  999.756 
Basic/0.1N NaOH/ 
60°C/1h  42.1  999.325 
Oxidative/ 30% H2O2 
/60°C/1h  59.2  999.293 
Thermal/80 C/24h  8.9  999.655 
Photo/UV 254nm/48h  0  999.788 
366nm/48h  0  999.771 
*Peak purity values in the range of 990-1000 indicate a 
homogeneous peak. 
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Fig. 2. Chromatogram of Tablet Sample Solution 
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Fig. 4. Chromatogram of Standard Solution 
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Fig. 5. Chromatogram of Blank for Base hydrolysis 
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Fig. 6. Chromatogram of Sample for Base hydrolysis 
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Fig. 7. Chromatogram of Blank for Oxidative degradation 
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Fig. 8. Chromatogram of Oxidative degradation 
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Fig. 9. Chromatogram of Thermal degradation 
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4. 2. Precision (Repeatability)  
Six  replicate  analysis  of  tablets  by  the 
proposed method were done. The area % RSD 
for  guanfacine  hydrochloride  was  0.4.  The 
results of the precision study indicate that the 
method  is  reliable(RSD  %<  2).  The 
intermediate precision (inter-day precision) of 
the  method  was  also  evaluated  using  two 
different  analysts  in  different  days  in  same 
laboratory. Results are shown in Table 3. 
 
4. 3. Accuracy 
Accuracy  of  the  method  was  studied  by 
recovery  experiments.  The  recovery 
experiments were performed by adding known 
amounts  of  the  drugs  in  the  placebo.  The 
recovery was performed at three levels, 80%, 
100% and 120% of the label claim of the tablet 
(2mg  of  guanfacine  hydrochloride).  Placebo 
equivalent to fifteen tablet was transferred into 
a 100 mL volumetric flask, and the amount of 
guanfacine  hydrochloride  at  80%,  100%  and 
120% of the label claim of the tablet was added 
to  it. The recovery samples were prepared  as 
per  the  procedure  mentioned  in  sample 
preparation  of  dosage  form.  Three  samples 
were  prepared  for  each  recovery  level.  The 
solutions  were  further  analyzed,  and  the 
percentage  recoveries  were  calculated.  The 
results are shown in Table 4. 
 
Table  3.  Result  of  precision  of  test  method  of 
Guanfacine Hydrochloride. 
 
Sample 
number 
Analyst-I 
(Intra-day 
precision) 
Analyst-II 
(Inter-day 
precision) 
1  99.36  99.73 
2  99.11  99.47 
3  99.45  98.65 
4  98.89  98.99 
5  99.65  99.25 
6  98.71  99.69 
Mean  99.02  99.12 
% RSD  0.36  0.42 
 
 
         Table 4. Recovery result of Guanfacine Hydrochloride 
 
Level of addition (%)  Actual Concentration 
(µg/mL) 
Found Concentration 
(µg/mL)  Mean % Recovery 
80  241.2  239.2  99.2 
100  302.3  303.7  100.5 
120  362.7  362.7  100.2 
 
4. 4. Linearity 
Linearity  solutions  for  the  method  were 
prepared from stock guanfacine hydrochloride 
solution  (3000  µg/mL)  at  six  different 
concentrations levels tested from 30 µg/mL to 
450  µg/mL  (10  to  150%  of  the  assay 
concentration  of  guanfacine  hydro-chloride, 
300 µg/mL). Each linearity level solutions were 
injected  in  triplicate.  The  calibration  graphs 
were obtained by plotting peak area verses the 
concentration of  the  analyte. The  equation of 
the calibration curve is y = 13.917x + 1.8702. 
The calibration graph was plotted and found to 
be linear in the aforementioned concentrati-ons 
with correlation coefficient 0.999. 
 
4. 5. Limit of Detection (LOD) and Limit of 
Quantitation (LOQ). 
The  LOD  and  LOQ  for  guanfacine 
hydrochloride were determined at a signal-to-
noise  ratio  of  3:1  and  10:1,  respectively,  by 
injecting  a  series  of  dilute  standard  solutions 
with known concentrations
 (12). The LOD for 
guanfacine hydrochloride 0.011 µg/mL, and the 
LOQ was 0.038 µg/mL, respectively. 
 
4. 6. Robustness 
To  determine  the  robustness  of  the 
developed method experimental condition were 
purposely  altered  and  the  resolution  between 
the  peaks  of  guanfacine  hydrochloride  and 
adjacent  base  degradation  product  were 
evaluated.  V. K. Ahirrao et al / Int. J. Ind. Chem., Vol. 2, No. 2, 2011, pp. 69-77 
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The flow rate of the mobile phase was 1.0 
mL/min. To study the effect of flow rate on the 
resolution, it was changed by 0.2 units from 0.8 
to  1.2mL/min.  The  effect  of  percent  organic 
strength on resolution was studied by varying 
acetonitrile from –10 to  +10%. The effect of 
column temperature on resolution was studied 
at 25 C and 35 C instead of 30 C while the 
other  mobile  phase  components  were  held 
constant  stated  in  chromatographic  condition. 
The robustness results are shown in Table 5. 
 
Table 5. Results of robustness study. 
 
Parameters  Variations  Resolution* 
Flow rate 
0.8 mL/min  2.9 
1.2 mL/min  2.7 
Mobile phase 
31.5 mL of Acetonitrile  3.3 
38.5 mL of Acetonitrile  2.5 
Temperature 
25°C  2.9 
35°C  2.8 
 
*Resolution  between  analyte  peak  and  adjacent  base 
degradant. 
 
4. 7. Solution Stabilty  
The  stability  of  the  guanfacine 
hydrochloride  bulk  drug  solution  and  tablet 
assay  solutions  were  measured  at  the  time 
intervals of 24 and 48 hours. The stability of 
standard  solutions  was  determined  by 
comparing results of area% and peak purity of 
analyte. The area% values were within 0.5 % 
after  48  hours.  The  results  indicate  that  the 
solution  was  stable  for  48  hours  at  ambient 
temperature as there was no formation of any 
unknown peak and solution remains stable. The 
Peak  purity  value  were  999.721.  Assay  of 
tablet sample solution was determined at both 
intervals  which  is  within  0.5%  of  the  initial 
value. 
 
5. Conclusion 
The  method  developed  for  quantitative 
determination  of  guanfacine  hydrochloride  is 
rapid,  precise,  accurate  and  selective.  The 
method  was  completely  validated  showing 
satisfactory  data  for  all  method-validated 
parameters  tested.  The  developed  method  is 
stability-indicating  as  all  degradants  were 
resolved betterly and can be used for assessing 
the stability of  guanfacine hydrochloride as a 
bulk  drug.  The  developed  method  can  be 
conveniently used for the assay determination 
of guanfacine hydrochloride in bulk drugs and 
pharmaceutical dosage form in quality control 
department.  
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